Journal Club

Developmental defects in Huntington’s disease show that axonal growth and microtubule reorganization require NUMA1 journal summary

Overview of Huntington’s Disease (HD)

  • HD is caused by an abnormal CAG expansion in the huntingtin gene.

  • The mutated protein (mHTT) has a long polyglutamine tract.

  • Classic symptoms appear in adulthood but developmental abnormalities occur earlier, around 13 weeks gestation.

Key Findings from Recent Research

  • Axonal Growth Defects: HD causes defects in axonal growth during developmental stages.

  • NUMA1 Role: The protein NUMA1 (nuclear/mitotic apparatus protein 1) is downregulated in HD, leading to microtubule disorganization in growth cones.

  • Rescue Potential: Restoring NUMA1 levels can rescue axonal growth in HD models.

Detailed Mechanisms

Axonal Growth and Microtubule Reorganization

  • Axonal growth is facilitated by the growth cone, a motile structure at the axon’s tip, which responds to extracellular guidance cues.

  • Cytoskeletal Dynamics: The growth cone's cytoskeleton is restructured to support axonal outgrowth:

    • Push from axonal shaft via microtubule polymerization.

    • Pull from retrograde actin flow at the front of the growth cone.

NUMA1 and Microtubule Bundling

  • NUMA1 downregulation is associated with microtubule bundling defects.

  • Its expression influences the microtubule network, facilitating proper growth cone morphology.

  • Growth Cone Size: Larger growth cones are observed in NUMA1-deficient conditions.

Research Methods and Observations

Animal Model Studies

  • Studies utilized HD knockin mouse models (HdhQ7/Q111) to analyze axonal growth patterns.

  • In Utero Electroporation: Membrane-targeted red fluorescent protein (mem-RFP) was used to label neurons in the developing cortex.

  • Measurements of axonal length indicated shorter axons in HdhQ7/Q111 embryos compared to controls (HdhQ7/Q7).

  • Age-Related Findings: At postnatal day (P) 0 and P4, axonal length remained significantly shortened in HD mice.

Microtubule Dynamics in Growth Cones

  • Proteomic analyses provided insights into protein compositions of growth cones, revealing a decrease in NUMA1 levels in HD affected mice.

  • Comparisons of growth cone fractions showed differential expression of proteins, with downregulated transcription factors and structural proteins.

Role of MicroRNAs in NUMA1 Regulation

  • NUMA1 downregulation appears to be post-transcriptionally regulated by increased levels of miR-124 in HD.

  • Inhibition of miR-124 using antagomiR-124 led to increased NUMA1 levels and reversed axonal growth defects in HD neurons.

Implications of Findings

  • Developmental Impact: The research highlights that axonal growth deficits in HD start early in development, affecting neural connectivity long before clinical symptoms emerge.

  • Therapeutic Potential: Targeting NUMA1 or its regulatory mechanisms could offer novel therapeutic strategies for HD, potentially delaying its clinical onset.

Experimental Techniques

  1. Immunoblotting: To assess protein levels across genotypes and conditions.

  2. qRT-PCR: Used to evaluate mRNA expression levels of NUMA1 and associated microRNAs.

  3. In Vitro Neuron Cultures: Axonal growth characteristics were measured in controlled environments.

  4. Mass Spectrometry Proteomics: Identified and quantified differences in protein compositions in growth cones.

Statistical Analysis

  • Statistical significance was determined using appropriate tests for the model types (e.g., unpaired t-tests, ANOVA) with specific p-values noted for comparisons.

Conclusion

  • The study underscores the importance of proper axonal growth and cytoskeletal organization in the pathology of Huntington's disease, imparting insights into potential pathways for therapeutic intervention.